Al-Aly and colleagues noted association for GLP-1 use and reduced risk for several cardiovascular events like heart failure (HR = 0.89
Protein has emerged as a focal point of this change
However, emerging evidence suggests that GLP-1RAs could be beneficial for specific eating disorder symptoms in individuals with obesity who do not have diabetes, potentially reducing binge eating, dietary disinhibition, overall eating disorder psychopathology, and concerns about body shape (Chao et al., 2019)
For those who are uninsured or who have insurance that doesn't cover Wegovy, Novo Nordisk also offers a self-pay program with reduced cash prices
However, some individuals may still experience occasional bloating or early satiety with prolonged therapy, which should be assessed during routine follow-up visits